PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

Plain-language summary

This is a registry study that tracks disease outcomes and inherited (germline) gene mutations in people with prostate cancer. People diagnosed with prostate cancer at any stage who live in the United States can take part. It is a non-phase observational study and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Prostate Cancer Clinical Trials Consortium

Start date

5/3/2021

Estimated completion

2/26/2036

Countries

United States

Related genes

Locations

• Baltimore, United States
• New York, United States
• Seattle, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Have prostate cancer (any stage of disease or survivorship) diagnosed or documented through one of the following:

  * tissue biopsy, and/or
  * PSA greater than 100 ng/dL (1ng/ml), and/or
  * clear radiographic evidence of disease
* Live in the United States (including Puerto Rico, Guam, American Samoa, US Virgin Islands, Northern Mariana Islands)

Exclusion Criteria:

* Unable or unwilling to provide all of the necessary information for eligibility
* Incomplete inclusion criteria